GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptive Biotechnologies Corp (FRA:1HM) » Definitions » Gross Profit

Adaptive Biotechnologies (FRA:1HM) Gross Profit : €91.9 Mil (TTM As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Adaptive Biotechnologies Gross Profit?

Adaptive Biotechnologies's gross profit for the three months ended in Mar. 2024 was €21.9 Mil. Adaptive Biotechnologies's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was €91.9 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Adaptive Biotechnologies's gross profit for the three months ended in Mar. 2024 was €21.9 Mil. Adaptive Biotechnologies's Revenue for the three months ended in Mar. 2024 was €38.5 Mil. Therefore, Adaptive Biotechnologies's Gross Margin % for the quarter that ended in Mar. 2024 was 56.89%.

Adaptive Biotechnologies had a gross margin of 56.89% for the quarter that ended in Mar. 2024 => Durable competitive advantage

During the past 7 years, the highest Gross Margin % of Adaptive Biotechnologies was 77.10%. The lowest was 55.63%. And the median was 68.06%.

Warning Sign:

Adaptive Biotechnologies Corp gross margin has been in long-term decline. The average rate of decline per year is -3.1%.


Adaptive Biotechnologies Gross Profit Historical Data

The historical data trend for Adaptive Biotechnologies's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adaptive Biotechnologies Gross Profit Chart

Adaptive Biotechnologies Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial 56.52 62.35 92.96 120.27 86.86

Adaptive Biotechnologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.71 28.63 17.40 24.00 21.92

Competitive Comparison of Adaptive Biotechnologies's Gross Profit

For the Biotechnology subindustry, Adaptive Biotechnologies's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adaptive Biotechnologies's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adaptive Biotechnologies's Gross Profit distribution charts can be found below:

* The bar in red indicates where Adaptive Biotechnologies's Gross Profit falls into.



Adaptive Biotechnologies Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Adaptive Biotechnologies's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=156.143 - 69.282
=86.9

Adaptive Biotechnologies's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=38.523 - 16.607
=21.9

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €91.9 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Adaptive Biotechnologies's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=21.9 / 38.523
=56.89 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Adaptive Biotechnologies  (FRA:1HM) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Adaptive Biotechnologies had a gross margin of 56.89% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Adaptive Biotechnologies Gross Profit Related Terms

Thank you for viewing the detailed overview of Adaptive Biotechnologies's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Adaptive Biotechnologies (FRA:1HM) Business Description

Traded in Other Exchanges
Address
1165 Eastlake Avenue East, Seattle, WA, USA, 98109
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease ("MRD") in patients with multiple myeloma ("MM"), B cell acute lymphoblastic leukemia ("ALL") and chronic lymphocytic leukemia ("CLL") and is also available as a CLIA-validated laboratory developed test ("LDT") for patients with other lymphoid cancers, including diffuse large B-cell lymphoma ("DLBCL").

Adaptive Biotechnologies (FRA:1HM) Headlines

No Headlines